Haisco Pharmaceutical Group (002653) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 2025 reached ¥892 million, up 18.60% year-over-year, while net profit attributable to shareholders dropped 49.31% to ¥46.6 million.

• Excluding non-recurring items, net profit rose 69.25% to ¥50.3 million, indicating strong core business performance.

• Cash flow from operating activities decreased 68.95% year-over-year to ¥18.3 million.

Financial highlights

• Basic and diluted EPS were ¥0.04, down 50% year-over-year.

• Total assets increased 1.86% from year-end to ¥6.92 billion.

• Shareholders’ equity decreased 2.31% to ¥4.12 billion.

• R&D expenses surged 71.40% year-over-year to ¥143.1 million, reflecting increased investment in innovation.

• Other income fell 79.76% due to lower government support.

Outlook and guidance

• Increased R&D investment aims to enhance competitiveness and support future growth.